Improving pancreatic islet cell survival for diabetes treatment
Enhanced pancreatic islet cell engraftment by treatment with serpin B1
This study is looking at how a special protein called Serpin B1 can help improve the survival of insulin-producing cells after they are transplanted, which could make pancreatic islet transplants a better option for people with Type 1 diabetes and help them manage their condition more easily.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serplus Technology, LLC NIH-funded |
| Lab location | 1 site (San Mateo, United States) |
| Project ID | NIH-10383270 on NIH RePORTER |
What this research studies
This research focuses on enhancing the survival of pancreatic islet cells, which are crucial for insulin production in diabetes patients. It investigates the use of a protein called Serpin B1 to improve the engraftment of these cells after transplantation. By exploring new methods to promote tolerance and reduce immune rejection, the study aims to make pancreatic islet transplantation a more viable option for patients with Type 1 diabetes. If successful, this approach could lead to better management of diabetes and potentially reduce the need for insulin therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals with Type 1 diabetes who are struggling to manage their condition with insulin therapy alone.
Not a fit: Patients with Type 2 diabetes or those who do not have diabetes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with Type 1 diabetes, potentially reducing their reliance on insulin.
How similar studies have performed: Previous research has shown promise in using similar immunoregulatory proteins to improve transplant outcomes, indicating potential for success in this novel approach.
Where this research is happening
San Mateo, United States
- Serplus Technology, LLC — San Mateo, United States (Active)
Researchers
- Principal investigator: Pemberton, Philip — Serplus Technology, LLC
- Study coordinator: Pemberton, Philip
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.